Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply

Lancet. 2023 Nov 18;402(10415):1834. doi: 10.1016/S0140-6736(23)01618-5.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Dermatitis, Atopic* / drug therapy
  • Double-Blind Method
  • Humans
  • Severity of Illness Index
  • Treatment Outcome